As first-line treatments for a variety of malignancies, including BLCA, immune checkpoint inhibitors (ICIs) targeting the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-ligand-1 (PD-L1) pathways have been discovered. Here, CTLA4 is linked to bladder transitional cell carcinoma.